<DOC>
	<DOCNO>NCT03061812</DOCNO>
	<brief_summary>The purpose randomize , open-label , 2-arm , Phase 3 study ass ass efficacy , safety tolerability rovalpituzumab tesirine versus topotecan participant advance metastatic Small Cell Lung Cancer ( SCLC ) high level delta-like protein 3 ( DLL3 ) first disease progression follow front-line platinum-based chemotherapy .</brief_summary>
	<brief_title>Study Comparing Rovalpituzumab Tesirine Versus Topotecan Subjects With Advanced Metastatic Small Cell Lung Cancer With High Levels Delta-like Protein 3 ( DLL3 ) Who Have First Disease Progression During Following Front-line Platinum-based Chemotherapy ( TAHOE )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Participant must histologically cytologically confirm advanced metastatic Small Cell Lung Cancer ( SCLC ) document first disease progression follow frontline platinumbased systemic regimen Tumor must high Deltalike protein 3 ( DLL3 ) expression define â‰¥ 75 % tumor cell stain positive accord VENTANA DLL3 immunochemistry ( IHC ) Assay . Participant must measurable disease , define per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 per Central Radiographic Assessment Committee ( CRAC ) . Participant must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Participant must recovery Grade 0 1 clinically significant toxicity ( exclude alopecia ) prior initiation study drug administration . Participant document history cerebral vascular event ( stroke transient ischemic attack ) , unstable angina , myocardial infarction , cardiac symptom consistent New York Heart Association Class ( NYHA ) III IV within 6 month prior first dose study drug . Participant known leptomeningeal metastasis . Participant receive one prior systemic therapy regimen SCLC . Participant serious infection within 2 week prior randomization , include Grade 3 high viral , bacterial , fungal infection . Participant history active malignancy SCLC within past 2 year prior study entry , exception situ cancer curatively treat . Participant prior exposure topotecan , irinotecan topoisomerase I inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rovalpituzumab tesirine</keyword>
	<keyword>metastatic</keyword>
	<keyword>Delta-like protein 3 ( DLL3 )</keyword>
	<keyword>topotecan</keyword>
	<keyword>Small cell lung cancer ( SCLC )</keyword>
</DOC>